Malgorzata Monika Trawinska

Dr. Malgorzata Monika Trawinska

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Elisabetta AbruzzeseElisabetta Abruzzese
Elisabetta Abruzzese
SAStefano Aureli
Stefano Aureli
FBFrancesco Bondanini
Francesco Bondanini
MCMariavita Ciccarone
Mariavita Ciccarone
ECElisabetta Cortis
Elisabetta Cortis
PFPaolo de Fabritiis
Paolo de Fabritiis
The overwhelming success of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients has opened a discussion among medical practitioners and the lay public on the real possibility of pregnancy and conception in females and males with CML. In the past 10 years this subject has acquired growing interest in the scientific community and specific knowledge has been obtained “from bench to bedside”. Embryological, pharmacological, and pathophysiological studies have merged with worldwide patient databases to provide a roadmap to a successful pregnancy and birth in CML patients. Male conception does not seem to be affected by TKI therapy, since this class of drugs is neither genotoxic nor mutagenic, however, caution should be used specially with newer drugs for which little or no data are available. In contrast, female patients should avoid TKI therapy specifically during the embryonic stage of organogenesis (5–12 weeks) because TKIs can be teratogenic. In the last 15 years, 41 pregnancies have been followed in our center. A total of 11 male conceptions and 30 female pregnancies are described. TKI treatment was generally terminated as soon as the pregnancy was discovered (3–5 weeks), to avoid exposure during embryonic period and to reduce the risk of needing treatment in the first trimester. Eleven pregnancies were treated with interferon, imatinib or nilotinib during gestation. Nilotinib plasma levels in cord blood and maternal blood at delivery were studied in 2 patients and reduced or absent placental crossing of nilotinib was observed. All of the patients were managed by a multidisciplinary team of physicians with obligatory hematological and obgyn consultations. This work provides an update on the state of the art and detailed description of pregnancy management and outcomes in CML patients.

15 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Elisabetta AbruzzeseElisabetta Abruzzese
Elisabetta Abruzzese
MBMonica Bocchia
Monica Bocchia
Malgorzata Monika TrawinskaMalgorzata Monika Trawinska
Malgorzata Monika Trawinska
Donatella RaspadoriDonatella Raspadori
Donatella Raspadori
FBFrancesco Bondanini
Francesco Bondanini
Simona BernardiSimona Bernardi
Simona Bernardi
A Deep Molecular Response (DMR), defined as a BCR::ABL1 transcript at levels ≤ 0.01% by RT-qPCR, is the prerequisite for the successful interruption of treatment among patients with Chronic Myeloid Leukemia (CML). However, approximately 50% of patients in Treatment-Free Remission (TFR) studies had to resume therapy after their BCR::ABL1 transcript levels rose above the 0.1% threshold. To improve transcript detection sensitivity and accuracy, transcript levels can be analyzed using digital PCR (dPCR). dPCR increases BCR::ABL1 transcript detection sensitivity 10–100 fold; however, its ability to better select successful TFR patients remains unclear. Beyond the role of the immune system, relapses may be due to the presence of residual leukemic stem cells (LSCs) that are transcriptionally silent. Flow cytometry can be used to identify and quantify circulating bone marrow Ph+ LSCs CD34+/CD38− co-expressing CD26 (dipeptidylpeptidase-IV). To date, the significance of circulating Ph+ LSCs in TFR is unclear. The aim of this work is to compare and examine the values obtained using the three different methods of detecting minimal residual disease (MRD) in CML at RNA (RT-qPCR and dPCR) and LSC (flowcytometry) levels among patients in TFR or exhibiting a DMR. The twenty-seven patients enrolled received treatment with either imatinib (12), dasatinib (6), nilotinib (7), bosutinib (1), or interferon (1). Twelve patients were in TFR, while the rest exhibited a DMR. The TFR patients had stopped therapy for less than 1 year (3), <3 years (2), 6 years (6), and 17 years (1). Blood samples were collected and tested using the three methods at the same time. Both d-PCR and LSCs showed higher sensitivity than RT-qPCR, exhibiting positive results in samples that were undetectable using RT-qPCR (17/27). None of the patients tested negative with d-PCR; however, 23/27 were under the threshold of 0.468 copies/μL, corresponding to a stable DMR. The results were divided into quartiles, and the lowest quartiles defined the lowest MRD. These data were strongly correlated in 15/27 patients, corresponding to almost half of the TFR patients. Indeed, the TFR patients, some lasting up to 17 years, corresponded to the lowest detectable DMR categories. To the best of our knowledge, this is the first attempt to analyze and compare DMRs in a CML population using standard (RT-qPCR) and highly sensitive (dPCR and LSCs) methods.

7 November 2018 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
Elisabetta AbruzzeseElisabetta Abruzzese
Elisabetta Abruzzese
PFPaolo de Fabritiis
Paolo de Fabritiis
Malgorzata Monika TrawinskaMalgorzata Monika Trawinska
Malgorzata Monika Trawinska
PNPasquale Niscola
Pasquale Niscola
JAJane FELICITY Apperley
Jane FELICITY Apperley
MMMichael J. Mauro
Michael J. Mauro
Tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) have revamped entirely the approach to this diagnosis. What once was a predictably fatal disease (with the exception of rare patients with long term success from interferon and those who could undergo and survive allogeneic stem cell transplant) is now a highly treatable condition, with ‘functional cure’ (sustained remission after TKI cessation) a possibility for many. For the patient with CML diagnosed in the chronic phase in the current era, initial discussions typically focus on risk stratification and optimized choice among several approved TKI options, with stem cell transplantation evaluation deferred and reserved for cases of advanced phase disease and sequential or highly selective TKI resistance.

13 March 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
Francesca PalandriFrancesca Palandri
Francesca Palandri
GAGiuseppe Auteri
Giuseppe Auteri
Elisabetta AbruzzeseElisabetta Abruzzese
Elisabetta Abruzzese
GCGiovanni Caocci
Giovanni Caocci
Massimiliano BonifacioMassimiliano Bonifacio
Massimiliano Bonifacio
Giuseppe A. PalumboGiuseppe A. Palumbo
Giuseppe A. Palumbo
Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9% to 26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.

17 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Francesca PalandriFrancesca Palandri
Francesca Palandri
Giuseppe A. PalumboGiuseppe A. Palumbo
Giuseppe A. Palumbo
Massimiliano BonifacioMassimiliano Bonifacio
Massimiliano Bonifacio
Elena Maria ElliElena Maria Elli
Elena Maria Elli
Mario TiribelliMario Tiribelli
Mario Tiribelli
Massimo BrecciaMassimo Breccia
Massimo Breccia
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early ruxolitinib monotherapy failure and worse outcomes. We investigated predictors of early ruxolitinib discontinuation and death on therapy in 889 patients included in the “RUX-MF” retrospective study. Overall, 172 patients were alive on ruxolitinib after ≥5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after ≥5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after <5 yrs (early death on ruxolitinib, EDR). The cumulative incidence of the blast phase was similar in LTR and STR patients (p = 0.08). Overall survival (OS) was significantly longer in LTR pts (p = 0.002). In multivariate analysis, PLT < 100 × 109/L, Hb < 10 g/dL, primary MF, absence of spleen response at 3 months and ruxolitinib starting dose <10 mg BID were associated with higher probability of STR. Assigning one point to each significant variable, a prognostic model for STR (STR-PM) was built, and three groups were identified: low (score 0–1), intermediate (score 2), and high risk (score ≥ 3). The STR-PM may identify patients at higher risk of failure with ruxolitinib monotherapy who should be considered for alternative frontline strategies.

1 June 2006 in Blood
Verified
Journal Article
Closed access
PDF file
Elisabetta AbruzzeseElisabetta Abruzzese
Elisabetta Abruzzese
GPGiovanni Del Poeta
Giovanni Del Poeta
RBRosanna Barbato
Rosanna Barbato
SFStefano Fratoni
Stefano Fratoni
Malgorzata Monika TrawinskaMalgorzata Monika Trawinska
Malgorzata Monika Trawinska
SASergio Amadori
Sergio Amadori